Learning from prepandemic data to forecast viral escape.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
20
07
2022
accepted:
06
09
2023
medline:
27
10
2023
pubmed:
12
10
2023
entrez:
11
10
2023
Statut:
ppublish
Résumé
Effective pandemic preparedness relies on anticipating viral mutations that are able to evade host immune responses to facilitate vaccine and therapeutic design. However, current strategies for viral evolution prediction are not available early in a pandemic-experimental approaches require host polyclonal antibodies to test against
Identifiants
pubmed: 37821700
doi: 10.1038/s41586-023-06617-0
pii: 10.1038/s41586-023-06617-0
pmc: PMC10599991
doi:
Substances chimiques
Viral Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
818-825Subventions
Organisme : NIGMS NIH HHS
ID : F32 GM141007
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, e20201181 (2020).
pubmed: 32692348
pmcid: 7372514
doi: 10.1084/jem.20201181
Dong, J. et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat. Microbiol. 6, 1233–1244 (2021).
pubmed: 34548634
pmcid: 8543371
doi: 10.1038/s41564-021-00972-2
Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 Spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44–57.e9 (2021).
pubmed: 33259788
pmcid: 7676316
doi: 10.1016/j.chom.2020.11.007
Greaney, A. J. et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat. Commun. 12, 4196 (2021).
Greaney, A. J. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29, 463–476.e6 (2021).
pubmed: 33592168
pmcid: 7869748
doi: 10.1016/j.chom.2021.02.003
Greaney, A. J. et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci. Transl Med. 13, eabi9915 (2021).
pubmed: 34103407
pmcid: 8369496
doi: 10.1126/scitranslmed.abi9915
Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850–854 (2021).
pubmed: 33495308
pmcid: 7963219
doi: 10.1126/science.abf9302
Starr, T. N. et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 597, 97–102 (2021).
pubmed: 34261126
pmcid: 9282883
doi: 10.1038/s41586-021-03807-6
Starr, T. N., Greaney, A. J., Dingens, A. S. & Bloom, J. D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med. 2, 100255 (2021).
pubmed: 33842902
pmcid: 8020059
doi: 10.1016/j.xcrm.2021.100255
Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 597, 103–108 (2021).
pubmed: 34280951
pmcid: 9341430
doi: 10.1038/s41586-021-03817-4
Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022).
pubmed: 35016194
doi: 10.1038/s41586-021-04385-3
Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593–602 (2022).
pubmed: 35714668
pmcid: 9385493
doi: 10.1038/s41586-022-04980-y
Greaney, A. J. et al. A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. PLoS Pathog. 18, e1010248 (2022).
pubmed: 35134084
pmcid: 8856557
doi: 10.1371/journal.ppat.1010248
Greaney, A. J. et al. The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. PLoS Pathog. 18, e1010592 (2022).
pubmed: 35767821
pmcid: 9275729
doi: 10.1371/journal.ppat.1010592
Doud, M. B., Lee, J. M. & Bloom, J. D. How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin. Nat. Commun. 9, 1386 (2018).
pubmed: 29643370
pmcid: 5895760
doi: 10.1038/s41467-018-03665-3
Dingens, A. S., Arenz, D., Weight, H., Overbaugh, J. & Bloom, J. D. An antigenic atlas of HIV-1 escape from broadly neutralizing antibodies distinguishes functional and structural epitopes. Immunity 50, 520–532.e3 (2019).
pubmed: 30709739
pmcid: 6435357
doi: 10.1016/j.immuni.2018.12.017
Obermeyer, F. et al. Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. Science 376, 1327–1332 (2022).
pubmed: 35608456
doi: 10.1126/science.abm1208
Pucci, F. & Rooman, M. Prediction and evolution of the molecular fitness of SARS-CoV-2 variants: introducing SpikePro. Viruses 13, 935 (2021).
pubmed: 34070055
pmcid: 8158131
doi: 10.3390/v13050935
Beguir, K. et al. Early computational detection of potential high-risk SARS-CoV-2 variants. Comput. Biol. Med. 155, 106618 (2023).
pubmed: 36774893
pmcid: 9892295
doi: 10.1016/j.compbiomed.2023.106618
Frazer, J. et al. Disease variant prediction with deep generative models of evolutionary data. Nature 599, 91–95 (2021).
pubmed: 34707284
doi: 10.1038/s41586-021-04043-8
Hopf, T. A. et al. Mutation effects predicted from sequence co-variation. Nat. Biotechnol. 35, 128–135 (2017).
pubmed: 28092658
pmcid: 5383098
doi: 10.1038/nbt.3769
Riesselman, A. J., Ingraham, J. B. & Marks, D. S. Deep generative models of genetic variation capture the effects of mutations. Nat. Methods 15, 816–822 (2018).
pubmed: 30250057
pmcid: 6693876
doi: 10.1038/s41592-018-0138-4
Gong, L. I., Suchard, M. A. & Bloom, J. D. Stability-mediated epistasis constrains the evolution of an influenza protein. eLife 2, e00631 (2013).
pubmed: 23682315
pmcid: 3654441
doi: 10.7554/eLife.00631
Starr, T. N. et al. Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution. Science 377, 420–424 (2022).
pubmed: 35762884
doi: 10.1126/science.abo7896
Haddox, H. K., Dingens, A. S., Hilton, S. K., Overbaugh, J. & Bloom, J. D. Mapping mutational effects along the evolutionary landscape of HIV envelope. eLife 7, e34420 (2018).
pubmed: 29590010
pmcid: 5910023
doi: 10.7554/eLife.34420
Doud, M. B. & Bloom, J. D. Accurate measurement of the effects of all amino-acid mutations on influenza hemagglutinin. Viruses 8, 155 (2016).
pubmed: 27271655
pmcid: 4926175
doi: 10.3390/v8060155
Wu, N. C. et al. Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses. Science 368, 1335–1340 (2020).
pubmed: 32554590
pmcid: 7412937
doi: 10.1126/science.aaz5143
Roop, J. I., Cassidy, N. A., Dingens, A. S., Bloom, J. D. & Overbaugh, J. Identification of HIV-1 envelope mutations that enhance entry using macaque CD4 and CCR5. Viruses 12, 241 (2020).
pubmed: 32098152
pmcid: 7077290
doi: 10.3390/v12020241
Duenas-Decamp, M., Jiang, L., Bolon, D. & Clapham, P. R. Saturation mutagenesis of the HIV-1 envelope CD4 binding loop reveals residues controlling distinct trimer conformations. PLoS Pathog. 12, e1005988 (2016).
pubmed: 27820858
pmcid: 5098743
doi: 10.1371/journal.ppat.1005988
Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295–1310.e20 (2020).
pubmed: 32841599
pmcid: 7418704
doi: 10.1016/j.cell.2020.08.012
Chan, K. K., Tan, T. J. C., Narayanan, K. K. & Procko, E. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants. Sci. Adv. 7, eabf1738 (2021).
pubmed: 33597251
pmcid: 7888922
doi: 10.1126/sciadv.abf1738
Flynn, J. M. et al. Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms. eLife 11, e77433 (2022).
pubmed: 35723575
pmcid: 9323007
doi: 10.7554/eLife.77433
Lin, C.-P. et al. Deriving protein dynamical properties from weighted protein contact number. Proteins 72, 929–935 (2008).
pubmed: 18300253
doi: 10.1002/prot.21983
Chothia, C. & Janin, J. Principles of protein–protein recognition. Nature 256, 705–708 (1975).
pubmed: 1153006
doi: 10.1038/256705a0
Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024–1042.e21 (2020).
pubmed: 32991844
pmcid: 7494283
doi: 10.1016/j.cell.2020.09.037
Cerutti, G. et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 29, 819–833.e7 (2021).
pubmed: 33789084
pmcid: 7953435
doi: 10.1016/j.chom.2021.03.005
Rodriguez-Rivas, J., Croce, G., Muscat, M. & Weigt, M. Epistatic models predict mutable sites in SARS-CoV-2 proteins and epitopes. Proc. Natl Acad. Sci. USA 119, e2113118119 (2022).
pubmed: 35022216
pmcid: 8795541
doi: 10.1073/pnas.2113118119
Bangaru, S. et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science 370, 1089–1094 (2020).
pubmed: 33082295
pmcid: 7857404
doi: 10.1126/science.abe1502
Ginex, T. et al. The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: the case of the spike A222V mutation. PLoS Pathog. 18, e1010631 (2022).
pubmed: 35816514
pmcid: 9302720
doi: 10.1371/journal.ppat.1010631
Zhao, L. P. et al. Rapidly identifying new Coronavirus mutations of potential concern in the Omicron variant using an unsupervised learning strategy. Preprint at Res. Sq. https://doi.org/10.21203/rs.3.rs-1280819/v1 (2022).
doi: 10.21203/rs.3.rs-1280819/v1
pubmed: 36597533
pmcid: 9810236
Tada, T. et al. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. eBioMedicine 78, 103944 (2022).
pubmed: 35465948
pmcid: 9021600
doi: 10.1016/j.ebiom.2022.103944
Hie, B., Zhong, E. D., Berger, B. & Bryson, B. Learning the language of viral evolution and escape. Science 371, 284–288 (2021).
pubmed: 33446556
doi: 10.1126/science.abd7331
Notin, P. et al. TranceptEVE: combining family-specific and family-agnostic models of protein sequences for improved fitness prediction. Preprint at bioRxiv https://doi.org/10.1101/2022.12.07.519495 (2022).
Smyth, D. S. et al. Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater. Nat. Commun. 13, 635 (2022).
pubmed: 35115523
pmcid: 8813986
doi: 10.1038/s41467-022-28246-3
Buck, T. K. et al. Neutralizing antibodies against Lassa virus lineage I. mBio 13, e0127822 (2022).
pubmed: 35730904
doi: 10.1128/mbio.01278-22
Borisevich, V. et al. Escape from monoclonal antibody neutralization affects henipavirus fitness in vitro and in vivo. J. Infect. Dis. 213, 448–455 (2016).
pubmed: 26357909
doi: 10.1093/infdis/jiv449
Wang, Z. et al. Architecture and antigenicity of the Nipah virus attachment glycoprotein. Science 375, 1373–1378 (2022).
pubmed: 35239409
doi: 10.1126/science.abm5561
Xu, K. et al. Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody. PLoS Pathog. 9, e1003684 (2013).
pubmed: 24130486
pmcid: 3795035
doi: 10.1371/journal.ppat.1003684
Dang, H. V. et al. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections. Nat. Struct. Mol. Biol. 26, 980–987 (2019).
pubmed: 31570878
pmcid: 6858553
doi: 10.1038/s41594-019-0308-9
Dang, H. V. et al. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins. Nat. Struct. Mol. Biol. 28, 426–434 (2021).
pubmed: 33927387
doi: 10.1038/s41594-021-00584-8